Irvine, CA (PRWEB) February 25, 2013
EP Global Communications, Inc. (the Company), (Pink Sheets: EPGL.PK) is pleased to provide shareholders with the following major updates for the month of March 2013 and beyond:
First, the Company announces that up to 12 new medical device patents will be filed in the month of March, 2013. These patent filings will coincide with previously mentioned device technologies in research and development and additional new technologies which have not been publicly announced as yet. In addition, at least 3 new FDA 510k Applications will be put in process in March, 2013.
Second, the MPDD device will be released on March 25, 2013. Very positive reviews from Pain Physicians and inquiries from patients who are in pain and desperately seeking solutions, has prompted the Company to advance the timetable for MPDD. Shareholders can expect additional updates on this development as the time draws closer.
Third, the MPTT (Muscle Pain Trigger-Point Treatment) is being put on a track to be released by December, 2013 pending FDA 510k approval. The MPTT FDA 510k approval is expected by September, 2013. At least two other FDA 510k applications will be pending and the Company is optimistic those will be approved in the same approximate time frame. As the research and design phases of new devices is a fluid situation, more FDA 510 and PMA filings may be announced in the near future.
Fourth, DTC restrictions on some brokers are expected to be lifted at any moment. The Company counsel has filed all requisite documents and all brokers should have access to EPGL stock electronic deposit services, shortly.
Fifth, as shareholders know, the Company has achieved Current Information status with OTC Markets. Now, the Company plans to graduate the EPGL symbol to OTCQX by end of year 2013.
Following that movement, the next goal will be to bring the Company to NASDAQ or NYSE sometime in 2014.
The next major shareholder shall be on March 29, 2013, followed by a live conference call the same day at 6:00PM EST. Shareholders can expect other national PR updates whenever the Company feels it necessary upon developments or breaking Company news. Shareholders should always monitor Twitter for daily and weekly updates and announcements. The Company reminds shareholders that there will be a live Twitter Q&A today at 6:00PM EST.
About EP Global Communications, Inc.
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Read the full story at http://www.prweb.com/releases/2013/2/prweb10464659.htm.
Copyright©2012 Vocus, Inc.
All rights reserved